TOMEGAVAX, INC.

Company Information
Address 4640 SW Macadam Ave Ste 130A
Portland, OR, 97239-4283


Information

DUNS: 968353347

# of Employees: 11


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B

    Amount: $297,434.00

    Abstract Although an efficient prophylactic vaccine is available for hepatitis B virus HBV chronic hepatitis B CHB affects up to million people worldwide and despite advances remains mostly ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. A Cytomegalovirus Vectored Chagas Disease Therapeutic Vaccine

    Amount: $224,959.00

    Abstract The goal of this project is to utilize cytomegalovirus CMV vectors to develop a therapeutic vaccine against Trypanosoma cruzi the causative agent of Chagas disease Although the most commo ...

    SBIRPhase I2016Department of Health and Human Services
  3. A Cytomegalovirus-based therapeutic vaccine against oncogenic human papillomaviruses

    Amount: $1,876,513.00

    Abstract High risk human papillomaviruses HPV cause cervical cancer the second most common neoplasm among women globally and a large proportion of oropharyngeal cancers Although prophylactic vacc ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  4. An effector memory T cell-based therapeutic cervical cancer vaccine

    Amount: $224,671.00

    DESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors carrying oncogenes of high risk human papillomaviruses (HPV) as novel therapeutic va ...

    SBIRPhase I2014Department of Health and Human Services
  5. CMV Vectored Herpes Simplex Vaccine

    Amount: $299,863.00

    DESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors in the development of a therapeutic vaccine against herpes simplex virus 2 (HSV-2), t ...

    STTRPhase I2014Department of Health and Human Services
  6. A human cytomegalovirus-based immunotherapy for HIV-1

    Amount: $2,965,403.00

    DESCRIPTION The ultimate goal of this project is to develop an immunotherapy for human immunodeficiency virus HIV based on a spread deficient cytomegalovirus CMV derived vaccine expressing andq ...

    SBIRPhase II2014Department of Health and Human Services
  7. A Synthetic Human Cytomegalovirus Vaccine Platform

    Amount: $573,060.00

    DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish per ...

    STTRPhase I2013Department of Health and Human Services
  8. Spread-deficient HCMV-vectored vaccines

    Amount: $299,835.00

    DESCRIPTION (provided by applicant): The goal of this project is to establish human cytomegalovirus (HCMV) as a new human vaccine vector platform. In non-human primate models, CMV-vectored vaccines ha ...

    SBIRPhase I2012Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government